Active pharmaceutical ingredients acquired in an asset acquisition.

No definition available.

Name:	anip_ActivePharmaceuticalIngredientsAcquiredInAssetAcquition
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of inventory recognized as of the acquisition date.

+ References

No definition available.

+ Details

Name:	anip_AssetAcquisitionRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents a contingent liability that has not been recognized because it is not both estimable and probable.

+ References

No definition available.

+ Details

Name:	anip_ContingentLiabilityNotRecognized
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Contingent liability recognized in an asset acquisition.

+ References

No definition available.

+ Details

Name:	anip_ContingentLiabilityRecognized
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents cumulative amortization expense related to transaction.

+ References

No definition available.

+ Details

Name:	anip_CumulativeAmortizationExpense
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.

+ References

No definition available.

+ Details

Name:	anip_FairValuesInputsDiscountRate
Namespace Prefix:	anip_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Finished goods acquired in an asset acquisition.

+ References

No definition available.

+ Details

Name:	anip_FinishedGoodsAcquiredInAssetAcquisition
Namespace Prefix:	anip_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the number of approved products under product portfolio.

+ References

No definition available.

+ Details

Name:	anip_NumberOfApprovedProductsUnderProductPortfolio
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of approved products with launches pending under product portfolio.

+ References

No definition available.

+ Details

Name:	anip_NumberOfApprovedProductsWithLaunchesPendingUnderProductPortfolio
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of commercial products under product portfolio.

+ References

No definition available.

+ Details

Name:	anip_NumberOfCommercialProductsUnderProductPortfolio
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of filed products under product portfolio.

+ References

No definition available.

+ Details

Name:	anip_NumberOfFiledProductsUnderProductPortfolio
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of generic drug products.

+ References

No definition available.

+ Details

Name:	anip_NumberOfGenericDrugProducts
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of in-development products under product portfolio.

+ References

No definition available.

+ Details

Name:	anip_NumberOfInDevelopmentProductsUnderProductPortfolio
Namespace Prefix:	anip_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of years for the amount payable on the contingent profit share.

+ References

No definition available.

+ Details

Name:	anip_NumberOfYearsContingentProfitSharePayable
Namespace Prefix:	anip_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

+ Details

Name:	us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 928
-SubTopic 340
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetsGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 3
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275

+ Details

Name:	us-gaap_ImpairmentOfIntangibleAssetsFinitelived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_LongtermPurchaseCommitmentPeriod
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of cash outflow for fees classified as other.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 25
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585

+ Details

Name:	us-gaap_PaymentsForFees
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

+ Details

Name:	us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Fair value portion of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258

+ Details

Name:	us-gaap_PropertyPlantAndEquipmentFairValueDisclosure
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.

+ References

No definition available.

+ Details

Name:	us-gaap_PropertyPlantAndEquipmentUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.

+ References

No definition available.

+ Details

Name:	us-gaap_ResearchAndDevelopmentInProcess
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_AcquiredAndaIntangibleAssetsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=anip_MarketingAndDistributionRightsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=anip_PrivateCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=anip_AmerigenPharmaceuticalsLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=anip_CoeptisPharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=anip_PharmaceuticsInternationalIncAndBasAndaLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=anip_TevaPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=anip_ImpaxLaboratoriesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=anip_MilestoneOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=anip_MilestoneTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=anip_MilestoneThreeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

FAIR VALUE DISCLOSURES - Acquired (Details) $ in Thousands	1 Months Ended						3 Months Ended			6 Months Ended
FAIR VALUE DISCLOSURES - Acquired (Details) $ in Thousands	May 31, 2020 USD ($) product	Jan. 31, 2020 USD ($) product	Jun. 30, 2019 USD ($) product	Mar. 31, 2019 USD ($) product	Jan. 31, 2019 USD ($)	Apr. 30, 2018 USD ($) product	Jun. 30, 2020 USD ($)	Dec. 31, 2019 USD ($)	Jun. 30, 2019 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2019 USD ($)
Payments to Acquire Intangible Assets										$ 58,130	$ 20,834
Finite-Lived Intangible Assets, Gross							$ 352,649	$ 307,225		352,649
Research and development							3,035		$ 5,773	9,379	10,146
Intangible asset impairment charge							0		0	0	0
Amortization of Intangible Assets							10,000		8,400	20,100	23,400
Research and Development in Process										3,753	2,324
Acquired ANDA intangible assets
Finite-Lived Intangible Assets, Gross							103,394	64,704		$ 103,394
Finite-Lived Intangible Asset, Useful Life										8 years 10 months 24 days
Marketing and distribution rights
Finite-Lived Intangible Assets, Gross							17,657	10,923		$ 17,657
Finite-Lived Intangible Asset, Useful Life										5 years 8 months 12 days
Private Company [Member]
Number of generic products \| product	1
Total asset acquisition	$ 200
Transaction costs	$ 7
Finite-Lived Intangible Asset, Useful Life	7 years
Intangible asset impairment charge										$ 0
Amerigen Pharmaceuticals, Ltd.
Number of generic products \| product		23
Total asset acquisition		$ 56,800
Contingent liability not recognized		$ 25,000
Period of contingent payments		4 years
Number of commercial products under product portfolio		10
Number of approved products with launches pending under product portfolio		3
Number of filed products under product portfolio		4
Number of in-development products under product portfolio		4
Number of approved products under product portfolio		2
Payments to Acquire Intangible Assets		$ 48,900
Transaction costs		$ 700
Finite-Lived Intangible Asset, Useful Life		7 years
Research and development		$ 3,800
Inventory recognized		8,400
API inventory recognized		1,700
Finished goods inventory recognized		$ 6,700
Contingent liability recognized							$ 200			200
Intangible asset impairment charge										0
Amerigen Pharmaceuticals, Ltd. \| Discount rate
Fair Values Inputs Discount Rate		8.00%
Amerigen Pharmaceuticals, Ltd. \| Acquired ANDA intangible assets
Finite-Lived Intangible Assets, Gross		$ 38,500
Amerigen Pharmaceuticals, Ltd. \| Marketing and distribution rights
Finite-Lived Intangible Assets, Gross		$ 6,700
Coeptis Pharmaceuticals, Inc. [Member]
Number of generic products \| product			7
Total asset acquisition			$ 2,300
Contingent liability not recognized			12,000						$ 12,000		$ 12,000
Transaction costs			$ 24
Pharmaceutics International, Inc and BAS ANDA LLC [Member]
Payments to Acquire Intangible Assets								$ 500
Finite-Lived Intangible Asset, Useful Life								10 years
Intangible asset impairment charge										0
Teva Pharmaceuticals [Member]
Number of generic products \| product				35
Payments to Acquire Intangible Assets				$ 2,500	$ 16,000
Transaction costs				10
Finite-Lived Intangible Assets, Gross				$ 2,500	9,200
Finite-Lived Intangible Asset, Useful Life				10 years
Intangible asset impairment charge										0
Cumulative Amortization Expense					$ 6,800
Teva Pharmaceuticals [Member] \| Discount rate
Fair Values Inputs Discount Rate				15.00%	12.00%
Impax Laboratories, Inc. [Member]
Number of generic products \| product						2
Payments to Acquire Intangible Assets						$ 2,300
Transaction costs						100
Finite-Lived Intangible Assets, Gross						$ 1,000
Finite-Lived Intangible Asset, Useful Life						10 years
Intangible asset impairment charge										$ 0
Purchase commitment period						17 months
Equipment fair value						$ 58
Property useful life						5 years
Research and Development in Process						$ 1,300
Impax Laboratories, Inc. [Member] \| Discount rate
Fair Values Inputs Discount Rate						75.00%
Impax Laboratories, Inc. [Member] \| Discount rate \| Minimum
Fair Values Inputs Discount Rate						10.00%
Impax Laboratories, Inc. [Member] \| Discount rate \| Maximum
Fair Values Inputs Discount Rate						15.00%
Impax Laboratories, Inc. [Member] \| Milestone One [Member]
Contingent liability not recognized						$ 25,000
Impax Laboratories, Inc. [Member] \| Milestone Two [Member]
Contingent liability not recognized						15,000
Impax Laboratories, Inc. [Member] \| Milestone Three [Member]
Contingent liability not recognized						$ 10,000